Yarrow Bioscience director reports option holdings
Yarrow Bioscience, Inc. reports initial insider holdings for director William Richard White.
Rhea-AI Filing Summary
Yarrow Bioscience, Inc. reports initial insider holdings for director William Richard White. Following a merger effective July 27, 2026, a wholly owned subsidiary of VYNE Therapeutics Inc. merged into the prior Yarrow entity, and VYNE changed its name to Yarrow Bioscience, Inc. White holds a stock option directly to purchase 87,820 shares of Issuer Common Stock at an exercise price of $6.19 per share, expiring on April 17, 2036. One quarter of this option will vest on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to his continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
White William Richard
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) F1, F2, F3 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 87,820 contracts (Direct)
Footnotes (3)
- F1. Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer").
- F2. Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the Reporting Person in the Merger in exchange for options to purchase shares of common stock of Yarrow held by the Reporting Person prior to the Merger. At the Effective Time, the Issuer assumed each such Yarrow option, whether vested or unvested, and converted it into an option to purchase shares of Issuer Common Stock on the same terms and conditions as were in effect immediately prior to the Effective Time.
- F3. This option represents a right to purchase 87,820 shares of Issuer Common Stock, one quarter of which will vest on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Underlying option shares: 87,820 shares
Exercise price: $6.19 per share
Option expiration date: April 17, 2036
+2 more
5 metrics
Underlying option shares
87,820 shares
Right to purchase Issuer Common Stock held by director William Richard White
Exercise price
$6.19 per share
Exercise price of the 87,820-share stock option
Option expiration date
April 17, 2036
Expiration of the reported stock option position
Merger effective date
July 27, 2026
Effective Time of merger between a VYNE subsidiary and the prior Yarrow entity
Initial vesting date
April 17, 2027
One quarter of the 87,820-share option vests on this date
Key Terms
Effective Time, wholly owned subsidiary, Issuer Common Stock, par value, +1 more
5 terms
Effective Time regulatory
"Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary..."
The exact clock time when a regulatory filing, approval, or corporate action formally becomes legally active; from that moment the change is binding and can be acted on. Investors care because the effective time marks when ownership, rights, trading rules, or new securities take effect — like a light switch turning on a contract or transaction — which determines when risks, benefits and market reactions begin.
wholly owned subsidiary regulatory
"a wholly owned subsidiary of VYNE Therapeutics Inc. merged with and into Yarrow..."
A wholly owned subsidiary is a company whose entire ownership is held by another company (the parent), so the parent controls decisions, operations, and finances. Think of it as a fully controlled branch that runs as its own legal entity but whose results flow straight into the parent’s financial statements; investors watch these structures because they affect consolidated revenue, risk exposure, and how profits, liabilities, and cash flow are allocated across the corporate group.
Issuer Common Stock financial
"Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock")..."
par value financial
"Represents options to purchase shares of common stock, par value $0.0001, of the Issuer..."
Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.
vesting financial
"the remaining three quarters vesting in equal monthly installments over the following three years..."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Yarrow Bioscience’s (VYNE) Form 3 filing report for William Richard White?
The filing shows director William Richard White holding a stock option for 87,820 shares of Issuer Common Stock at $6.19 per share. The option expires on April 17, 2036 and follows Yarrow’s merger-related reorganization.
What is the exercise price and expiration of the reported Yarrow Bioscience (VYNE) option?
The reported stock option has an exercise price of $6.19 per share and an expiration date of April 17, 2036. These terms apply to the option covering 87,820 shares of Issuer Common Stock held directly by William Richard White.
What is the vesting schedule of William Richard White’s option at Yarrow Bioscience (VYNE)?
One quarter of the option will vest on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the next three years. Vesting is conditioned on William Richard White’s continued service to the issuer.
How did the Yarrow Bioscience (VYNE) merger affect William Richard White’s options?
At the merger’s Effective Time on July 27, 2026, the issuer assumed each prior Yarrow option and converted it into an option for Issuer Common Stock on the same terms. White’s 87,820-share option reflects this conversion.
What corporate changes around VYNE are described in this Yarrow Bioscience (VYNE) Form 3?
A wholly owned subsidiary of VYNE Therapeutics Inc. merged into the prior Yarrow entity on July 27, 2026. Yarrow became a wholly owned subsidiary, and VYNE changed its name to Yarrow Bioscience, Inc., now the issuer in this Form 3.
AI-generated analysis. How Rhea-AI works. Not financial advice.
